In 2019, Collategene, another plasmid drug developed by the Japanese company AnGes, containing recombinant human hepatocyte growth factor (HGF), received conditional marketing approval in Japan.[14] Collategene is used for the treatment of obstructive arteriosclerosis and thromboangiitis obliterans. The gene discussed is HGF; the disease is thromboangiitis obliterans.